Literature DB >> 300232

Relation of titred peripheral pattern ANA to anti-DNA and disease activity in systemic lupus erythematosus.

R J Weitzman, S E Walker.   

Abstract

This study compared the clinical usefulness of the peripheral pattern detected in immunofluorescent antinuclear antibody (ANA) testing with anti-DNA measured by the modified Farr technique. 48 patients with active or inactive systemic lupus erythematosus (SLE) were studied at one point in the course of their disease. There was no association between titres of serum giving a peripheral ANA pattern (tp-ANA) and anti-DNA values. Tp-ANA did not correlate with activity of SLE. In contrast with this finding, anti-DNA correlated with severity of renal disease, decreased serum complement, and number of SLE criteria. In a separate group of 9 patients with flare-ups of SLE, tp-ANA and anti-DNA fell as disease activity was controlled. Nevertheless, these two parameters were independent of one another. It was concluded that tp-ANA did not accurately reflect anti-DNA or activity of SLE.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 300232      PMCID: PMC1006628          DOI: 10.1136/ard.36.1.44

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  12 in total

1.  HEMOLYTIC COMPLEMENT IN SYNOVIAL FLUID.

Authors:  T J PEKIN; N J ZVAIFLER
Journal:  J Clin Invest       Date:  1964-07       Impact factor: 14.808

2.  SPECIFIC NUCLEAR REACTION PATTERN OF ANTIBODY TO DNA IN LUPUS ERYTHEMATOSUS SERA.

Authors:  S P CASALS; G J FRIOU; P O TEAGUE
Journal:  J Lab Clin Med       Date:  1963-10

3.  Patterns of nuclear fluorescence and DNA-binding activity.

Authors:  A Luciano; N F Rothfield
Journal:  Ann Rheum Dis       Date:  1973-07       Impact factor: 19.103

4.  The relation of immunoglobulin class, pattern of anti-nuclear antibody, and complement-fixing antibodies to DNA in sera from patients with systemic lupus erythematosus.

Authors:  N F Rothfield; B D Stollar
Journal:  J Clin Invest       Date:  1967-11       Impact factor: 14.808

5.  Immunoglobulin class and pattern of nuclear fluorescence in systemic lupus erythematosus.

Authors:  E N Gonzalez; N F Rothfield
Journal:  N Engl J Med       Date:  1966-06-16       Impact factor: 91.245

6.  Relationship of nuclear staining patterns with precipitating antibodies in systemic lupus erythematosus.

Authors:  E M Tan
Journal:  J Lab Clin Med       Date:  1967-11

7.  Immunofluorescent patterns and specificity of human antinuclear antibodies.

Authors:  Y B Bickel; E V Barnett; C M Pearson
Journal:  Clin Exp Immunol       Date:  1968-09       Impact factor: 4.330

8.  Significance of nuclear immunofluorescent patterns.

Authors:  C A Dorsch; C B Gibbs; M B Stevens; L E Shulman
Journal:  Ann Rheum Dis       Date:  1969-05       Impact factor: 19.103

9.  The range and specificity of antinuclear antibodies in systemic lupus erythematosus.

Authors:  D Alarcón-Segovia; E Fishbein; H Alcalá; E Olguín-Palacios; S Estrada-Parra
Journal:  Clin Exp Immunol       Date:  1970-04       Impact factor: 4.330

10.  Antinuclear antibodies, rheumatoid factor and C-reactive protein in serum of normal women using oral contraceptives.

Authors:  D R Kay; G G Bole; W J Ledger
Journal:  Arthritis Rheum       Date:  1971 Mar-Apr
View more
  3 in total

1.  Estrogen receptor alpha promotes lupus in (NZB×NZW)F1 mice in a B cell intrinsic manner.

Authors:  Dana E Tabor; Karen A Gould
Journal:  Clin Immunol       Date:  2016-10-29       Impact factor: 3.969

2.  Immunological abnormalities of aging: an analysis of T lymphocyte subpopulations of Werner's syndrome.

Authors:  M Goto; Y Horiuchi; K Okumura; T Tada; M Kawata; K Ohmori
Journal:  J Clin Invest       Date:  1979-09       Impact factor: 14.808

3.  The Effect of Biological Agents on Antinuclear Antibody Status in Patients with Psoriasis: A Single-Center Study.

Authors:  Ömer Kutlu; Pınar Çetinkaya; Tijen Şahin; Hatice Meral Ekşioğlu
Journal:  Indian Dermatol Online J       Date:  2020-11-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.